Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsAgeX Therapeutics, Inc. announced that ImStem Biotechnology, Inc. has dosed the first US multiple sclerosis patient with ImStem’s lead investigational drug candidate IMS001.
[AgeX Therapeutics, Inc. (BusinessWire, Inc.)]
Home Newsletters Cell Therapy News AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed...
